GATX (NYSE:GATX) 주식

GATX

GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.

Tesla's Sky-High Surge

Equities

News

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

GATX Corp

Live Nation Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) shares turned lower after the market close on Monday following reports that President Donald Trump is preparing to sign an executive order to <a href="https://www.benzinga.com/news/25/03/44571188/president-trump-plans-to-sign-executive-order-aimed-at-protecting-fans-from-exploitative-ticket-scal">stop ticket scalping</a>.
What Happened: CNBC reported Monday on &#8220;Closing Bell: Overtime&#8221; that Trump is set to sign an executive order targeting price gouging in the live entertainment industry. 
The Trump administration will reportedly direct the Federal Trade Commission (FTC) to work with the attorney general to enforce competition laws within the industry. The executive order is expected to direct the FTC to ensure price transparency and to take enforcement action to prevent unfair and deceptive competitive conduct. 
The Trump administration will also ask the Treasury Department to get involved by working with the attorney general to make sure ticket scalpers are abiding by the law.
A report on the initial adjustments is due within 180 days. At that point, the government will determine if any additional legislation is needed. 
President Trump is expected to sign the executive order in the Oval Office at 5:30 p.m. ET. CNBC reported American musician Kid Rock will be in attendance at the signing.
Live Nation is a live entertainment company comprised of Ticketmaster, Live Nation Concerts and Live Nation Media &amp; Sponsorship.
LYV Price Action:<a href="http://benzinga.com/quote/lyv"> Live Nation shares</a> were down 1.98% after hours, trading at $127.99 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44570070/tariffs-inflation-and-tumbling-markets-these-5-etfs-thrived-amid-the-chaos-last-week">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a></li>
</ul>
Photo: Shutterstock.

Entertainment

Government

Regulations

After-Hours Center

Movers

Live Nation Shares Slide As Trump Moves To Sign Executive Order On Ticket Scalping

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 20 years by 2.63% on an annualized basis producing an average annual return of 10.67%. Currently, Agnico Eagle Mines has a market capitalization of $54.57 billion. 
Buying $1000 In AEM: If an investor had bought $1000 of AEM stock 20 years ago, it would be worth $7,623.77 today based on a price of $108.46 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743462021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Agnico Eagle Mines Stock In The Last 20 Years

Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) has outperformed the market over the past 5 years by 5.06% on an annualized basis producing an average annual return of 22.7%. Currently, Houlihan Lokey has a market capitalization of $11.33 billion. 
Buying $1000 In HLI: If an investor had bought $1000 of HLI stock 5 years ago, it would be worth $2,892.19 today based on a price of $161.50 for HLI at the time of writing.
<h3>Houlihan Lokey's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743461108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Since its release on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) on March 13, "Adolescence" has been one of the most-watched series on the streaming platform, adding to the potential strong lineup <a href="https://www.benzinga.com/25/02/43700767/netflix-stock-attractive-at-all-time-highs-for-analyst-virtuous-circle-of-strong-subscriber-growth-more-revenue-and-growing-profit">of 2025 content.</a>
Billionaire Elon Musk shared a theory about the series, which has the show's co-writer clapping back at his allegations.
What Happened: Netflix<a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations"> ended the fourth quarter</a> with 301.63 million paid subscribers. The streaming giant could add to that figure throughout 2025 with many highly anticipated series coming back.
Adding to the 2025 early hype is "Adolescence."
While the series has drawn plenty of support, one social media user accused the series of "anti-white propaganda."
"Netflix has a show called Adolescence that's about a British knife killer who stabbed a girl to death on a bus and it's based on real-life cases such as the Southport murderer. So guess what. They race swapped the actual killer from a black man/migrant to a white boy and the story has it so he was radicalized online by the red pill movement. Just the absolute state of anti-white propaganda," journalist Ian Miles Cheong <a href="https://x.com/elonmusk/status/1902586606575313345">tweeted</a>.
The tweet drew the attention of Musk, who replied, "Wow."
Another X user was quick to point out some false items in Cheong's tweet, including that the series was written and filming began before Southport happened.
Jack Thorne, who co-wrote "Adolescence," is now speaking out to clear the air. Thorne said on a podcast that "nothing could be further from the truth" when discussing the race-swapping allegations, as reported by <a href="https://variety.com/2025/tv/global/adolescence-writer-rejects-race-swap-theory-elon-musk-1236352337/">Variety</a>.
"There is no part of this that's based on a true story, not one single part," Thorne said.
The series co-writer said having a white boy in the series isn't about making a point about race.
"We're not making a point about race with this. We are making a point about masculinity. We're trying to get inside a problem. We're not saying this is one thing or another, we're saying that this is about boys."
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
 Why It's Important: The series drew 24.3 million views in its first week on Netflix and an additional 42 million views in its second week, ranking first among English-language shows each week.
On <a href="https://www.imdb.com/title/tt31806037/">IMDb</a>, the series ranks number one in popularity and has an 8.3 rating out of 10. The series also has top <a href="https://www.rottentomatoes.com/tv/adolescence">ratings </a>on Rotten Tomatoes, with a critic rating of 99% and an audience score of 73%.
Musk's amplification of the anti-white propaganda post could keep some people from watching the series, which may be bad for Netflix.
The response from the show's co-writer is another example of how dangerous posts on social media can be in getting others to believe something just because another person said it was true.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/05/38776258/tesla-ceo-elon-musk-draws-parallel-between-netflixs-decision-to-focus-on-streaming-over-renting-dvds">Tesla CEO Elon Musk Draws Parallel Between Netflix&#8217;s Decision To Focus On Streaming Over Renting DVDs To EV Maker Doubling Down On Vehicle Autonomy</a></li>
</ul>
Photo: Shutterstock

Elon Musk Attacks Netflix Hit Series, Shares 'Anti-White Propaganda' Allegation: Here's How The Show's Writer Claps Back

Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) has outperformed the market over the past 15 years by 1.75% on an annualized basis producing an average annual return of 12.62%. Currently, Advanced Energy Indus has a market capitalization of $3.61 billion. 
Buying $100 In AEIS: If an investor had bought $100 of AEIS stock 15 years ago, it would be worth $593.83 today based on a price of $95.31 for AEIS at the time of writing.
<h3>Advanced Energy Indus's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743460214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Here's How Much $100 Invested In Advanced Energy Indus 15 Years Ago Would Be Worth Today

If your last name is Buffett, <a href="https://www.benzinga.com/personal-finance/25/03/44482365/warren-buffetts-son-wasnt-raised-like-a-billionaires-kid-he-mowed-lawns-and-cleaned-gutters-because-there-are-jerks-with-money-and-jerks-without">people assume you're rich</a>. Not just "doing well" rich. Private jet, personal sushi chef, champagne-for-breakfast rich. But according to Howard Buffett—Warren Buffett's son—you'd be wrong. Very wrong.
In a <a href="https://fortune.com/2012/11/21/the-children-of-the-rich-and-famous/">1990 Fortune interview</a>, Howard explained people often attempt to use him just to get something from his dad. "When I get back to my office this afternoon, there will be nine messages," he said. "Eight of them will be from people wanting something from my dad." That was decades ago. Before viral GoFundMes, LinkedIn pitches, and inboxes flooded with crypto ideas. Howard was already living in the shadow of the world's most famous value investor, fielding daily requests just for having the audacity to share a surname.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
And it wasn't just inbox clutter.
"One night at a restaurant," he recalled, "I pulled out my checkbook to pay the bill, and some guy says, ‘Gee, I wish I had that checkbook!' I didn't have the patience to tell him, ‘No, buddy, you really don't.'"
<h2 class="wp-block-heading">A Billionaire Dad… But Rent's Still Due</h2>
While Warren Buffett built a financial empire out of Omaha, his kids didn't grow up with butlers or gated mansions. In fact, Howard became a farmer—and a grounded one. At one point, he was paying his own father rent for the land. Because, yes, even if your dad is worth over $100 billion, Warren still wants you to understand the value of a dollar and in this case, the value of a lease agreement.&nbsp;
The Buffett kids—Howard, Susie, and Peter—have long echoed the same message: their dad's money isn't their money.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">Then Came the $600 Million Gift —Sort Of</h2>
Now, to be fair, Warren isn't stingy. He's just strategic. In 2012, as <a href="https://www.nbcnews.com/businessmain/warren-buffett-his-birthday-gives-kids-600m-972645">NBC News reported</a>, he rang in his 82nd birthday by giving each of his three kids a gift… about $600 million worth of Berkshire Hathaway stock. But there's a twist—this wasn't for shopping sprees or yachts. It was for their charitable foundations.
That move brought each child's philanthropic firepower to a billion-dollar level, while still aligning with their dad's core belief: "You should leave your children enough so they can do anything, but not so much that they can do nothing."
Translation? You're getting capital—but not carte blanche.
<h2 class="wp-block-heading">Buffett's Inbox Problem Became Doris's Mission</h2>
Of course, when word gets out that you're charitable—your mailbox turns into a wish list. When Warren Buffett pledged in 2006 to give away most of his wealth, <a href="https://www.politico.com/story/2014/05/warren-buffett-doris-sister-sunshine-lady-foundation-107104">Politico</a> reported he was swamped with letters asking for help. Instead of ignoring them, he called in reinforcement: his older sister Doris.
Doris set up the Letters Foundation, a kind of philanthropic triage unit where real people with real problems—often just victims of bad luck—could get help. According to Warren, Doris and her all-women team "believe a lot of people got short straws in life, and she wants to help them." And unlike most billionaire philanthropy, these weren't high-profile causes or gala-funded grants. These were everyday people in crisis, and Doris read their stories one by one.
See Also: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">So…Is Howard Rich Now?</h2>
Back in 1990, Howard insisted he wasn't rich. But since then, he's been entrusted with a charitable foundation sitting on hundreds of millions of dollars in assets—and growing. That doesn't make him personally wealthy in the traditional sense, but it does mean he's rich in influence, especially when it comes to causes he cares about—like food security and conservation.
<h2 class="wp-block-heading">In Buffett World, Legacy Over Luxury</h2>
Warren Buffett's legacy isn't just his investment track record—it's how deliberately <a href="https://www.benzinga.com/startups/24/11/41866296/with-warren-buffett-donating-99-of-his-fortune-whats-left-for-his-three-children-well-its-complicated">unspoiled he's kept his children</a>.&nbsp;
And if you're wondering how Warren himself defines rich? According to Alice Schroeder's biography of Buffett, "The Snowball: Warren Buffett and the Business of Life," he told student as the University of Georgia in 2001, "If you get to my age in life and nobody thinks well of you, I don't care how big your bank account is, your life is a disaster."
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Personal Finance

Billionaire Warren Buffett's Son Says Everyone Assumes He's Rich — 8 Out of 10 Messages a Day Are Just 'People Wanting Something From My Dad'

Earnings

BATL

Battalion Oil Q4 Adj EPS $(0.04) Up From $(1.02) YoY

Detroit automakers are attempting to reassure their employees as they work to mitigate challenges posed by President Donald Trump&#8217;s sweeping 25% tariffs on imported vehicles and auto parts set to go<a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip"> into effect on Thursday.&nbsp;</a>
What To Know: The Detroit Free Press said it <a href="https://www.freep.com/story/money/cars/ford/2025/03/30/gm-ford-leaders-assure-employees-companies-future-amid-auto-tariffs/82721842007/">obtained</a> internal memos dated March 27 from both General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>).
Ford CEO Jim Farley told employees in the memo that the company is still examining <a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase">potential impacts </a>from the tariffs, which it expects to be &#8220;likely to be significant." 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a>
&#8220;While Ford supports the president's vision of building a stronger auto industry and manufacturing base in the United States, the situation is dynamic and the impacts of the tariffs are likely to be significant across our industry — affecting automakers, suppliers, dealers and customers,&#8221; Farley wrote. 
He noted nearly 80% of the vehicles Ford sells in the states are made in the U.S. but, &#8220;this does not mean Ford is immune to the impact of tariffs, which could be meaningful.&#8221;
&#8220;I assure you that our Ford team has been and will continue to engage closely with the Trump administration as well as policymakers in the U.S., Canada, Mexico and other markets to help shape these critical trade and policy issues,&#8221; Farley added. 
The Detroit Free Press also reported that it obtained an unsigned internal memo from General Motors which noted the tariffs will have an impact on the company's manufacturing operations and supply chain, though it did not give exact figures or estimates. 
The memo did say GM leadership is planning to keep the company &#8220;nimble based on any tariffs announced by the U.S. administration,&#8221; and the company supports a strong U.S.-based auto industry. 
It also encouraged employees to focus on their work and on managing costs.&nbsp;
&#8220;We are in a strong position to navigate this dynamic situation and will continue to deliver for our customers, employees, and communities. Each of us can contribute by staying focused and delivering on plans for this year, maintaining a disciplined approach and managing discretionary costs,&#8221; the GM memo reads.&nbsp;
What Else: President Trump on Saturday expressed <a href="https://www.benzinga.com/markets/25/03/44552465/trump-unfazed-by-potential-auto-price-hikes-amid-new-tariffs-i-couldnt-care-less">his anticipation </a>for price increases in response to the tariffs on auto imports and reaffirmed his decision to raise tariffs in an effort to boost American manufacturing.
"I couldn't care less if they raise prices, because people are going to start buying American-made cars," Trump stated in an interview <a href="https://www.nbcnews.com/politics/donald-trump/trump-says-couldnt-care-less-automakers-raise-prices-tariffs-rcna198731">with</a> NBC News.&nbsp;
GM, F Price Action: General Motors shares ended Monday's session 0.75% higher at $47.03 and Ford shares closed 3.19% higher at $10.03, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44563161/trump-says-tiktok-has-a-lot-of-potential-buyers-deal-to-come-before-saturday-deadline">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44563161/trump-says-tiktok-has-a-lot-of-potential-buyers-deal-to-come-before-saturday-deadline">Trump Says TikTok Has &#8216;A Lot Of Potential Buyers,&#8217; Deal To Come Before Saturday Deadline</a></li>
</ul>
Photo: Shutterstock

Politics

Management

Ford, GM Executives Address Trump Tariffs In Internal Memos Aimed To Reassure Employees: Report

Guidance

Babcock & Wilcox Expects Full Year 2025 Adjusted EBITDA Of $70M - $85M

Babcock & Wilcox Reveals Discussions Regarding Refinancing Of Debt With Key Bondholders In Addition To Other Potential Asset Sales

TPCS

TechPrecision  Appoints Phillip E. Podgorski As Its New CFO, Effective Today

ELLO

Ellomay Capital Q4 Revenues $9.033M

Throughout the last three months, 12 analysts have evaluated Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $26.5, a high estimate of $33.00, and a low estimate of $22.00. This upward trend is evident, with the current average reflecting a 17.05% increase from the previous average price target of $22.64.
<img src="https://www.benzinga.com/files/images/story/2025/1743458491_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Unity Software's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Uerkwitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>Citizens Capital Markets</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Andrew Uerkwitz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$28.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Uerkwitz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Unity Software. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Unity Software compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Unity Software's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Unity Software's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/U/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Unity Software analyst ratings.</a>
<h2>Discovering Unity Software: A Closer Look</h2>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
<h3>Breaking Down Unity Software's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Unity Software's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -24.98%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Unity Software's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -26.85%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -3.85%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Unity Software's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.82%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.7, Unity Software faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Unity Software In The Eyes Of 12 Experts

Analysts' ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over the last quarter vary from bullish to bearish, as provided by 27 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">15</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $338.44, with a high estimate of $500.00 and a low estimate of $280.00. Witnessing a positive shift, the current average has risen by 5.09% from the previous average price target of $322.04.
<img src="https://www.benzinga.com/files/images/story/2025/1743458484_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$284.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>About Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 34.9%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -14.12%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -168.47%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.98%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 19.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know

Ratings for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) were provided by 24 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">14</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $1191.0, a high estimate of $1432.00, and a low estimate of $716.00. This current average has increased by 1.79% from the previous average price target of $1170.05. 
<img src="https://www.benzinga.com/files/images/story/2025/1743458476_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of ServiceNow among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$950.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1010.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1100.00</td>
<td>$1210.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1048.00</td>
<td>$1048.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1300.00</td>
<td>$1300.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1275.00</td>
<td>$1275.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1426.00</td>
<td>$1432.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1250.00</td>
<td>$1300.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1275.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1210.00</td>
<td>$1210.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$1300.00</td>
<td>$1300.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1250.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$1432.00</td>
<td>$1071.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Sell</td>
<td>$716.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$1300.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$1332.00</td>
<td>-</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1210.00</td>
<td>$1045.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ServiceNow. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ServiceNow compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of ServiceNow's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ServiceNow's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NOW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ServiceNow analyst ratings.</a>
<h2>About ServiceNow</h2>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
<h3>ServiceNow: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, ServiceNow showcased positive performance, achieving a revenue growth rate of 21.34% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: ServiceNow's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ServiceNow's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.06% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ServiceNow's ROA excels beyond industry benchmarks, reaching 1.98%. This signifies efficient management of assets and strong financial health.
Debt Management: ServiceNow's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.24.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ServiceNow Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)

Analysts' ratings for CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CryoPort, presenting an average target of $10.75, a high estimate of $11.00, and a low estimate of $10.00. Highlighting a 2.27% decrease, the current average has fallen from the previous average price target of $11.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743458458_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CryoPort. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CryoPort's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: CryoPort's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.97%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CryoPort's net margin is impressive, surpassing industry averages. With a net margin of -34.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CryoPort's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: CryoPort's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYRX

Expert Outlook: CryoPort Through The Eyes Of 4 Analysts

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high estimate of $567.00, and a low estimate of $407.00. This upward trend is apparent, with the current average reflecting a 0.91% increase from the previous average price target of $473.82.
<img src="https://www.benzinga.com/files/images/story/2025/1743458443_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vertex Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$567.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$520.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$407.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$450.00</td>
<td>$433.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$467.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$459.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$433.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$460.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$533.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vertex Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Vertex Pharmaceuticals Better</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 15.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 31.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.08%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews

Throughout the last three months, 22 analysts have evaluated Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $207.7, a high estimate of $240.00, and a low estimate of $130.00. This current average represents a 8.87% decrease from the previous average price target of $227.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1743458435_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Palo Alto Networks. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$230.00</td>
<td>$217.50</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$212.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Hold</td>
<td>$196.40</td>
<td>$196.40</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$212.50</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Adjusts</td>
<td>Hold</td>
<td>$180.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$190.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Adjusts</td>
<td>Sector Outperform</td>
<td>$200.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Palo Alto Networks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Palo Alto Networks compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Palo Alto Networks's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Palo Alto Networks's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PANW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Palo Alto Networks analyst ratings.</a>
<h2>About Palo Alto Networks</h2>
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
<h3>Palo Alto Networks's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Palo Alto Networks displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 14.29%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Palo Alto Networks's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Palo Alto Networks's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Palo Alto Networks's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: Palo Alto Networks's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PANW

The Analyst Verdict: Palo Alto Networks In The Eyes Of 22 Experts

In the current session, Watts Water Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) is trading at $203.92, after a 0.03% decrease. Over the past month, the stock decreased by 0.33%, and in the past year, by 1.03%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743458416_0.png" alt="Past Year Chart" />

<h3>Comparing Watts Water Technologies P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Watts Water Technologies has a lower P/E than the aggregate P/E of 27.5 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743458416_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Watts Water Technologies

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) has outperformed the market over the past 10 years by 8.54% on an annualized basis producing an average annual return of 18.98%. Currently, CyberArk Software has a market capitalization of $16.66 billion. 
Buying $100 In CYBR: If an investor had bought $100 of CYBR stock 10 years ago, it would be worth $614.77 today based on a price of $338.00 for CYBR at the time of writing.
<h3>CyberArk Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743458411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYBR

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Press Releases

GATX Corporation Announces Appointment of Senior Vice President, International

GATX Corporation Sets Date for 2024 Third-Quarter Earnings Release and Conference Call

GATX Corporation Reports 2024 Third-Quarter Results

GATX Corporation Announces Quarterly Dividend

GATX Corporation Receives Responsible Care® Excellence in Partnership Award

GATX Corporation Sets Date for 2024 Fourth-Quarter Earnings Release and Conference Call

GATX Corporation Reports 2024 Fourth-Quarter and Full-Year Results

GATX Corporation Announces Quarterly Dividend Increase

GATX Corporation to Present at the Stifel 2025 Transportation & Logistics Conference

GATX Corporation at the Stifel 2025 Transportation & Logistics Conference Cancelled

Comments

GATX

뉴스

파트너 / 기고자

벤징가 글로벌